Updated assay guides diagnosis of autoimmune liver disease
Answers from the Lab
Diagnosis of autoimmune liver disease can be challenging. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune hepatitis, primary biliary cholangitis (PBC), and liver disease of unknown etiology.
"The disease spectrum is broad, and disease boundaries may be blurred by overlapping features," Dr. Tebo says. "The panel should ideally be requested following observation of abnormal liver enzymes, as well as for the elimination of common causes of liver disease such as metabolic, genetic, viral, drug, or alcohol-induced hepatitis."
The assay includes tests for two types of antibodies associated with autoimmune hepatitis and one type that is highly suggestive of PBC. Test results should be interpreted in the context of clinical assessment.
"Detection of these antibodies in asymptomatic patients may suggest risk for future disease development, which would require close monitoring for disease onset," Dr. Tebo says.
Listen to learn more about Mayo Clinic Laboratories' ALDG2 assay.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluating patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cholangitis.
Evaluating patients with liver disease of unknown etiology.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.